High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases
- 1 December 2000
- journal article
- research article
- Published by Wiley in Histopathology
- Vol. 37 (6) , 536-545
Abstract
The hormone receptor (HR) status of breast cancer is an important prognostic factor and predictive parameter of the response to hormone therapy. Enzyme immunoassay (EIA) is currently the standard for determination of HR, but immunohistochemistry (IHC) represents a potentially useful alternative. We used IHC to determine HR status in a large prospective study and compared the results to those obtained by EIA. This study was designed to determine which technique should be used in daily practice in our institution which manages a large number of patients.Oestrogen (ER) and progesterone (PgR) receptor status was evaluated in a prospective series of 793 infiltrating breast cancers by IHC in paraffin‐embedded tissue sections, using antibodies 6F11 and 1A6, with a rigorous quality control of the methodology. ER were found to be significantly expressed in 81% of cases after IHC analysis and in 78% of cases by EIA. For PgR, the respective rates of positivity were 65% and 69%. The tumour HR level detected by either technique was significantly correlated with the value of tumour size, histological grade and S‐phase fraction. A significant link was observed between the percentage of labelled cells after IHC analysis and the amount of protein detected by EIA. Critical analysis of discordance found that, in the group of invasive lobular carcinomas, the rate of HR positivity was higher with IHC (84%) than with EIA (45%) and that, in the overall population, IHC was more specific than EIA, since cases with nonrelevant positivity related to intraductal normal or neoplastic cells expressing HR could be discarded. The cost of IHC analysis was found to be about one‐third of that of EIA.IHC is more sensitive, specific and economical than EIA. It should constitute the new standard technique provided that good quality assurance procedures are respected.Keywords
This publication has 23 references indexed in Scilit:
- Comparison of Standardized Immunohistochemical and Biochemical Assays for Estrogen and Progesterone Receptors in Breast CarcinomaPathology - Research and Practice, 1997
- New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistryThe Journal of Pathology, 1997
- Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay.Journal of Clinical Pathology, 1994
- Progesterone receptor determined by immunocytochemical and biochemical methods in human breast cancerJournal of Cancer Research and Clinical Oncology, 1992
- Quality control in immunocytochemistry: experiences with the oestrogen receptor assay.Journal of Clinical Pathology, 1992
- Determination of Estrogen Receptors in Paraffin-Embedded Tissue: Techniques and the value in breast cancer treatmentActa Oncologica, 1992
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991
- Demonstration of progesterone receptors in paraffin wax sections of breast carcinoma.Journal of Clinical Pathology, 1990
- Oestrogen receptor staining of paraffin‐embedded breast carcinomas following short fixation in formalin: A comparison with cytosolic and frozen section receptor analysesThe Journal of Pathology, 1990
- Identification of the major sources of error in estrogen receptor measurements for individual laboratories using both tissue and cytosol samplesEuropean Journal of Cancer and Clinical Oncology, 1989